Renaldo Guzmán

816 total citations
20 papers, 485 citations indexed

About

Renaldo Guzmán is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Renaldo Guzmán has authored 20 papers receiving a total of 485 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pathology and Forensic Medicine, 9 papers in Oncology and 5 papers in Genetics. Recurrent topics in Renaldo Guzmán's work include Lymphoma Diagnosis and Treatment (16 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Viral-associated cancers and disorders (3 papers). Renaldo Guzmán is often cited by papers focused on Lymphoma Diagnosis and Treatment (16 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Viral-associated cancers and disorders (3 papers). Renaldo Guzmán collaborates with scholars based in Mexico, India and Vietnam. Renaldo Guzmán's co-authors include Alejandra Talavera, Edna L. García, José C. Díaz‐Maqueo, Agustín Avilés, Agustin Avilés, María Teresa Rugeles López, M. Jesús Nambo and Serafín Delgado and has published in prestigious journals such as European Journal of Cancer, Gynecologic Oncology and American Journal of Hematology.

In The Last Decade

Renaldo Guzmán

20 papers receiving 456 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Renaldo Guzmán Mexico 12 313 254 94 86 73 20 485
Edna L. García Mexico 12 287 0.9× 230 0.9× 63 0.7× 87 1.0× 78 1.1× 29 473
José C. Díaz‐Maqueo Mexico 12 294 0.9× 261 1.0× 89 0.9× 89 1.0× 65 0.9× 34 529
F. B. Hagemeister United States 10 329 1.1× 304 1.2× 82 0.9× 45 0.5× 92 1.3× 25 564
E.‐W. Schwarze Germany 13 124 0.4× 284 1.1× 89 0.9× 113 1.3× 62 0.8× 37 470
Caroline Kuhlman United States 8 301 1.0× 338 1.3× 65 0.7× 99 1.2× 76 1.0× 12 596
Marzia Salvucci Italy 15 214 0.7× 321 1.3× 70 0.7× 146 1.7× 41 0.6× 27 716
Dan Painter United Kingdom 6 180 0.6× 251 1.0× 60 0.6× 98 1.1× 55 0.8× 10 460
S.A.M. van de Schans Netherlands 14 247 0.8× 209 0.8× 50 0.5× 44 0.5× 33 0.5× 26 462
Bruno Anglaret France 13 394 1.3× 241 0.9× 100 1.1× 97 1.1× 20 0.3× 31 762
JJ Spinelli Canada 8 184 0.6× 158 0.6× 72 0.8× 61 0.7× 23 0.3× 12 543

Countries citing papers authored by Renaldo Guzmán

Since Specialization
Citations

This map shows the geographic impact of Renaldo Guzmán's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Renaldo Guzmán with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Renaldo Guzmán more than expected).

Fields of papers citing papers by Renaldo Guzmán

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Renaldo Guzmán. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Renaldo Guzmán. The network helps show where Renaldo Guzmán may publish in the future.

Co-authorship network of co-authors of Renaldo Guzmán

This figure shows the co-authorship network connecting the top 25 collaborators of Renaldo Guzmán. A scholar is included among the top collaborators of Renaldo Guzmán based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Renaldo Guzmán. Renaldo Guzmán is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Avilés, Agustín, José C. Díaz‐Maqueo, Alejandra Talavera, et al.. (1997). Bone marrow protection with amifostine in the treatment of high-risk malignant lymphoma. European Journal of Cancer. 33(8). 1323–1325. 18 indexed citations
2.
Avilés, Agustín, et al.. (1996). Treatment of non-Hodgkin's lymphoma of waldeyer's ring: Radiotherapy versus chemotherapy versus combined therapy. European Journal of Cancer Part B Oral Oncology. 32(1). 19–23. 56 indexed citations
3.
Avilés, Agustín, Renaldo Guzmán, Edna L. García, & José C. Díaz‐Maqueo. (1996). Biological Modifiers (Etetrinate and Interferon Alfa 2a) in the Treatment of Refractory Cutaneous T-Cell Lymphoma. Cancer Biotherapy and Radiopharmaceuticals. 11(1). 21–24. 14 indexed citations
4.
Avilés, Agustín, et al.. (1996). Interferon alpha 2b as maintenance therapy in low grade malignant lymphoma improves duration of remission and survival. Leukemia & lymphoma. 20(5-6). 495–499. 34 indexed citations
5.
Avilés, Agustin, Renaldo Guzmán, Serafín Delgado, et al.. (1996). Intensive brief chemotherapy with hematopoietic growth factors as hematological support and adjuvant radiotherapy improve the prognosis in aggressive malignant lymphoma. American Journal of Hematology. 52(4). 275–280. 10 indexed citations
6.
Avilés, Agustín, et al.. (1995). Treatment of Refractory Low Grade Lymphoma with Chlorambucil Alternating with Interferon and Radiotherapy. PubMed. 10(4). 273–277. 2 indexed citations
7.
Avilés, Agustin, et al.. (1995). Results of a randomized study of early stage Hodgkin's disease using ABVD, EBVD, or MBVD. Medical and Pediatric Oncology. 24(3). 171–175. 7 indexed citations
8.
Avilés, Agustín, et al.. (1995). Malnutrition as an adverse prognostic factor in patients with diffuse large cell lymphoma.. PubMed. 26(1). 31–4. 33 indexed citations
9.
Avilés, Agustín, Renaldo Guzmán, Alejandra Talavera, Edna L. García, & José C. Díaz‐Maqueo. (1994). Randomized study for the treatment of adult advanced Hodgkin's disease: Epirubicin, vinblastine, bleomycin, and dacarbazine (EVBD) versus mitoxantrone, vinblastine, bleomycin, and dacarbazine (MVBD). Medical and Pediatric Oncology. 22(3). 168–172. 8 indexed citations
10.
Avilés, Agustín, et al.. (1993). Value of Serum Beta 2 Microglobulin as an Indicator of Early Relapse in Diffuse Large Cell Lymphoma. Leukemia & lymphoma. 9(4-5). 377–380. 11 indexed citations
11.
Avilés, Agustín, et al.. (1993). [The role of radiotherapy in the early stages of Hodgkin's disease].. PubMed. 44(3). 363–8. 1 indexed citations
12.
Díaz‐Maqueo, José C., et al.. (1992). Maintenance therapy with interferon alfa 2b in patients with diffuse large cell lymphoma. Investigational New Drugs. 10(4). 351–355. 21 indexed citations
13.
Avilés, Agustín, et al.. (1992). Beta 2 Microglobulin Level as an Indicator of Prognosis in Diffuse Large Cell Lymphoma. Leukemia & lymphoma. 7(1-2). 135–138. 17 indexed citations
14.
Avilés, Agustín, et al.. (1992). Angiocentric T‐cell lymphoma of the nose, paranasal sinuses and hard palate. Hematological Oncology. 10(3-4). 141–147. 29 indexed citations
15.
Avilés, Agustín, et al.. (1992). [Prognostic importance of beta-2-microglobulin in multiple myeloma].. PubMed. 44(2). 215–20. 2 indexed citations
16.
Avilés, Agustín, et al.. (1991). Is Surgery Necessary in the Treatment of Primary Gastric Non-Hodgkin Lymphoma?. Leukemia & lymphoma. 5(5-6). 365–369. 29 indexed citations
17.
Avilés, Agustin, José C. Díaz‐Maqueo, Alejandra Talavera, Renaldo Guzmán, & Edna L. García. (1991). Growth and development of children of mothers treated with chemotherapy during pregnancy: Current status of 43 children. American Journal of Hematology. 36(4). 243–248. 143 indexed citations
18.
Avilés, Agustín, et al.. (1991). Prognostic value of serum beta 2 microglobulin in primary gastric lymphoma. Hematological Oncology. 9(2). 115–121. 6 indexed citations
19.
Avilés, Agustín, et al.. (1990). Non-Hodgkin's lymphomas and pregnancy: Presentation of 16 cases. Gynecologic Oncology. 37(3). 335–337. 37 indexed citations
20.
Avilés, Agustín, et al.. (1990). Group risk classification of non-Hodgkin's lymphoma.. PubMed. 21(1). 11–6. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Edna L. García Breakdown of academic impact, for papers by José C. Díaz‐Maqueo Breakdown of academic impact, for papers by F. B. Hagemeister Breakdown of academic impact, for papers by E.‐W. Schwarze Breakdown of academic impact, for papers by Caroline Kuhlman Breakdown of academic impact, for papers by Marzia Salvucci Breakdown of academic impact, for papers by Dan Painter Breakdown of academic impact, for papers by S.A.M. van de Schans Breakdown of academic impact, for papers by Bruno Anglaret Breakdown of academic impact, for papers by JJ Spinelli
Rankless by CCL
2026